Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : PR001,Methylprednisolone
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Eli Lilly
Deal Size : $1,040.0 million
Deal Type : Acquisition
Lilly Completes Acquisition of Prevail Therapeutics
Details : Acquisition will set up a gene therapy program at Lilly, based on Prevail's portfolio of neuroscience assets, including the lead candidate, PR001, and will broaden Lilly's commitment to use novel modalities to address fatal genetic forms of neurodegenera...
Product Name : PR001
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 22, 2021
Lead Product(s) : PR001,Methylprednisolone
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Eli Lilly
Deal Size : $1,040.0 million
Deal Type : Acquisition
Lead Product(s) : PR001,Methylprednisolone
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Eli Lilly
Deal Size : $1,040.0 million
Deal Type : Acquisition
Lilly Announces Agreement to Acquire Prevail Therapeutics
Details : Acquisition will establish a gene therapy program at Lilly, anchored by Prevail's portfolio of neuroscience assets, and will broaden Lilly's commitment to use novel modalities to attempt to address otherwise fatal genetic forms of neurodegenerative disea...
Product Name : PR001
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
December 15, 2020
Lead Product(s) : PR001,Methylprednisolone
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Eli Lilly
Deal Size : $1,040.0 million
Deal Type : Acquisition
Lead Product(s) : PR001
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Prevail Therapeutics’ PR001 Gets Orphan Drug Designation By FDA
Details : The Company also announced that the FDA has granted Rare Pediatric Disease Designation for PR001 for the treatment of neuronopathic Gaucher disease (nGD), the most severe form of the condition.
Product Name : PR001
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 02, 2020
Lead Product(s) : PR001
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PR006,Methylprednisolone
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PR006 is an investigational AAV9 gene therapy delivering the GRN gene and is being developed as a potential therapy for patients with frontotemporal dementia with GRN mutations.
Product Name : PR006
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
November 30, 2020
Lead Product(s) : PR006,Methylprednisolone
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PR001,Methylprednisolone
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Company expects to initiate enrollment of the Phase 1/2 PROVIDE clinical trial of PR001 for Type 2 Gaucher disease patients in the fourth quarter of 2020 and currently anticipates it will provide the next update on PR001 biomarker and safety data for...
Product Name : PR001
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
November 18, 2020
Lead Product(s) : PR001,Methylprednisolone
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PR001,Methylprednisolone
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Company is developing PR001 for patients with Parkinson’s disease with GBA1 mutations (PD-GBA) and neuronopathic Gaucher disease (nGD). Prevail expects to start enrollment of the PROVIDE Phase 1/2 clinical trial of PR001 in the second half of 2020.
Product Name : PR001
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
October 27, 2020
Lead Product(s) : PR001,Methylprednisolone
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PR001
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Prevail Therapeutics Provides PR001 Program Update
Details : Company Advancing its Phase 1/2 Clinical Trial for the Treatment of Neuronopathic Gaucher Disease and Expects to Initiate Patient Dosing in First Half of 2020.
Product Name : PR001
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
September 01, 2020
Lead Product(s) : PR001
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PR006
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PR006 is being developed as a potential one-time gene therapy for FTD-GRN, a progressive neurodegenerative disease caused by mutations in the GRN gene that reduce production of progranulin.
Product Name : PR006
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
July 27, 2020
Lead Product(s) : PR006
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PR001
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Preclinical data demonstrate potential of Prevail’s AAV gene therapy approach to slow or halt progression in multiple neurodegenerative diseases.
Product Name : PR001
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 29, 2020
Lead Product(s) : PR001
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PR001
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The presentation will highlight preclinical data related to PR001 for PD-GBA and the design of PROPEL, Phase 1/2 clinical trial to evaluate the safety and efficacy of PR001 in patients with PD-GBA.
Product Name : PR001
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
March 31, 2020
Lead Product(s) : PR001
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable